297 related articles for article (PubMed ID: 15592580)
1. The use of 4-aminopyridine (fampridine) in demyelinating disorders.
Hayes KC
CNS Drug Rev; 2004; 10(4):295-316. PubMed ID: 15592580
[TBL] [Abstract][Full Text] [Related]
2. Fampridine-SR for multiple sclerosis and spinal cord injury.
Hayes KC
Expert Rev Neurother; 2007 May; 7(5):453-61. PubMed ID: 17492896
[TBL] [Abstract][Full Text] [Related]
3. Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis.
Fernandez O; Berger T; Hartung HP; Putzki N
Expert Rev Clin Pharmacol; 2012 Nov; 5(6):649-65. PubMed ID: 23146002
[TBL] [Abstract][Full Text] [Related]
4. Sustained-release fampridine for symptomatic treatment of multiple sclerosis.
Korenke AR; Rivey MP; Allington DR
Ann Pharmacother; 2008 Oct; 42(10):1458-65. PubMed ID: 18780812
[TBL] [Abstract][Full Text] [Related]
5. Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury.
Potter PJ; Hayes KC; Segal JL; Hsieh JT; Brunnemann SR; Delaney GA; Tierney DS; Mason D
J Neurotrauma; 1998 Oct; 15(10):837-49. PubMed ID: 9814639
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury.
Hayes KC; Potter PJ; Hansebout RR; Bugaresti JM; Hsieh JT; Nicosia S; Katz MA; Blight AR; Cohen R
Clin Neuropharmacol; 2003; 26(4):185-92. PubMed ID: 12897638
[TBL] [Abstract][Full Text] [Related]
7. Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury.
Segal JL; Hayes KC; Brunnemann SR; Hsieh JT; Potter PJ; Pathak MS; Tierney DS; Mason D
J Clin Pharmacol; 2000 Apr; 40(4):402-9. PubMed ID: 10761168
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury.
Hayes KC; Potter PJ; Hsieh JT; Katz MA; Blight AR; Cohen R
Arch Phys Med Rehabil; 2004 Jan; 85(1):29-34. PubMed ID: 14970964
[TBL] [Abstract][Full Text] [Related]
9. Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury.
Cardenas DD; Ditunno JF; Graziani V; McLain AB; Lammertse DP; Potter PJ; Alexander MS; Cohen R; Blight AR
Spinal Cord; 2014 Jan; 52(1):70-6. PubMed ID: 24216616
[TBL] [Abstract][Full Text] [Related]
10. Potassium channel blockers as an effective treatment to restore impulse conduction in injured axons.
Shi R; Sun W
Neurosci Bull; 2011 Feb; 27(1):36-44. PubMed ID: 21270902
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial.
Vollmer T; Henney HR
Clin Ther; 2009 Oct; 31(10):2206-14. PubMed ID: 19922891
[TBL] [Abstract][Full Text] [Related]
12. Dalfampridine in multiple sclerosis.
Goodman AD; Hyland M
Drugs Today (Barc); 2010 Sep; 46(9):635-9. PubMed ID: 20967295
[TBL] [Abstract][Full Text] [Related]
13. Sustained release oral fampridine in the treatment of multiple sclerosis.
Kachuck NJ
Expert Opin Pharmacother; 2009 Aug; 10(12):2025-35. PubMed ID: 19586420
[TBL] [Abstract][Full Text] [Related]
14. Sustained-release fampridine for multiple sclerosis.
Bever CT; Judge SI
Expert Opin Investig Drugs; 2009 Jul; 18(7):1013-24. PubMed ID: 19548855
[TBL] [Abstract][Full Text] [Related]
15. Potassium channel antagonists 4-aminopyridine and the T-butyl carbamate derivative of 4-aminopyridine improve hind limb function in chronically non-ambulatory dogs; a blinded, placebo-controlled trial.
Lim JH; Muguet-Chanoit AC; Smith DT; Laber E; Olby NJ
PLoS One; 2014; 9(12):e116139. PubMed ID: 25551385
[TBL] [Abstract][Full Text] [Related]
16. 4-Aminopyridine-sensitive neurologic deficits in patients with spinal cord injury.
Hayes KC; Potter PJ; Wolfe DL; Hsieh JT; Delaney GA; Blight AR
J Neurotrauma; 1994 Aug; 11(4):433-46. PubMed ID: 7837283
[TBL] [Abstract][Full Text] [Related]
17. Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium?
Foschi M; Lugaresi A
Expert Opin Pharmacother; 2019 Aug; 20(11):1309-1320. PubMed ID: 31237780
[No Abstract] [Full Text] [Related]
18. [4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis].
Husseini L; Leussink VI; Kieseier BC; Hartung HP
Nervenarzt; 2010 Feb; 81(2):203-11. PubMed ID: 20112006
[TBL] [Abstract][Full Text] [Related]
19. Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis.
Hayes KC
Neuropsychiatr Dis Treat; 2011; 7():229-39. PubMed ID: 21573085
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective Properties of 4-Aminopyridine.
Dietrich M; Hartung HP; Albrecht P
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33653963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
